Evidence map›Paper›PMID 36245281›Full record

ArticleThe EMBO journal2023

The disulfide catalyst QSOX1 maintains the colon mucosal barrier by regulating Golgi glycosyltransferases.

Tal Ilani, Nava Reznik, Noa Yeshaya, Tal Feldman, Patrick Vilela, Zipora Lansky, Gabriel Javitt, Michal Shemesh, Ori Brenner, Yoav Elkis and 4 more

Open access · hybridAbstract read
In one paragraph

Article in The EMBO journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Emerging cell and molecular targets for treating mucus hypersecretion in asthma.Allergology international : official journal of the Japanese Society of Allergology · 2024
    Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Tal IlaniDepartment of Chemical and Structural Biology, Weizmann Institute of Science, Rehovot, Israel.ORCID 0000-0003-2806-4455
Nava ReznikDepartment of Chemical and Structural Biology, Weizmann Institute of Science, Rehovot, Israel.ORCID 0000-0002-3926-077X
Noa YeshayaDepartment of Chemical and Structural Biology, Weizmann Institute of Science, Rehovot, Israel.ORCID 0000-0003-0385-870X
Tal FeldmanDepartment of Chemical and Structural Biology, Weizmann Institute of Science, Rehovot, Israel.
Patrick VilelaDepartment of Chemical and Structural Biology, Weizmann Institute of Science, Rehovot, Israel.ORCID 0000-0003-1693-0571
Zipora LanskyDepartment of Chemical and Structural Biology, Weizmann Institute of Science, Rehovot, Israel.
Gabriel JavittDepartment of Chemical and Structural Biology, Weizmann Institute of Science, Rehovot, Israel.
Michal ShemeshLife Sciences Core Facilities, Weizmann Institute of Science, Rehovot, Israel.
Ori BrennerDepartment of Veterinary Resources, Weizmann Institute of Science, Rehovot, Israel.
Yoav ElkisAlmog Diagnostic, Shoham, Israel.
Neta VarsanoDepartment of Chemical Research Support, Weizmann Institute of Science, Rehovot, Israel.
Ana M JaramilloDepartment of Immunology and Microbiology, School of Medicine, University of Colorado, Aurora, CO, USA.
Christopher M EvansDepartment of Immunology and Microbiology, School of Medicine, University of Colorado, Aurora, CO, USA.
Deborah FassDepartment of Chemical and Structural Biology, Weizmann Institute of Science, Rehovot, Israel.ORCID 0000-0001-9418-6069
Weizmann Institute of Science · ILUniversity of Colorado Denver · US

Funding

Role of Mucin in Lung Homeostasis and PathophysiologyR01HL080396 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Christopher M Evans · 2009 to 2026
$8.6M
Mechanisms of lung macrophage programming by MUC5B during health and diseaseR01HL130938 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI EVANS, CHRISTOPHER M · 2016 to 2025
$5.2M
NHLBI NIH HHS R01 HL080396NHLBI NIH HHS R01 HL130938
6 · The paper itself

Abstract

Mucus is made of enormous mucin glycoproteins that polymerize by disulfide crosslinking in the Golgi apparatus. QSOX1 is a catalyst of disulfide bond formation localized to the Golgi. Both QSOX1 and mucins are highly expressed in goblet cells of mucosal tissues, leading to the hypothesis that QSOX1 catalyzes disulfide-mediated mucin polymerization. We found that knockout mice lacking QSOX1 had impaired mucus barrier function due to production of defective mucus. However, an investigation on the molecular level revealed normal disulfide-mediated polymerization of mucins and related glycoproteins. Instead, we detected a drastic decrease in sialic acid in the gut mucus glycome of the QSOX1 knockout mice, leading to the discovery that QSOX1 forms regulatory disulfides in Golgi glycosyltransferases. Sialylation defects in the colon are known to cause colitis in humans. Here we show that QSOX1 redox control of sialylation is essential for maintaining mucosal function.

Indexed as

GlycosyltransferasesGolgi ApparatusIntestinal MucosaOxidoreductases Acting on Sulfur Group DonorsAnimalsColonDisulfidesGlycoproteinsMiceMucinsDisulfidesGlycoproteinsGlycosyltransferasesMucinsOxidoreductases Acting on Sulfur Group DonorsQSOX1 protein, humanQSOX1 protein, mousecolonglycosyltransferasesmucusredox homeostasissulfhydryl oxidase

Identifiers

PMID36245281
PMCPMC9841341
OpenAlexW4306392299

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.